Nachrichten zur Hims & Hers Health Aktie

Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”, NYSE: HIMS) today announced its intention to offer, subject…

Detailed price information for Hims & Hers Health Inc (HIMS-N) from The Globe and Mail including charting and trades.…

Hims & Hers Health rises 3.34% to $25.05 today, showing mixed technical signals and resistance at $25.53 for potential moves.…

Wrapping up Q1 earnings, we look at the numbers and key takeaways for the healthcare technology stocks, including Hims &…

Proceeds intended to be used to preserve financial flexibility as Hims Hers executes on its international expansion strategy, including…

Hims & Hers Health rebounds post-GLP-1 shift; 2026 revenue target $3B and Eucalyptus upside.…

Hims & Hers Health (HIMS) is back in focus after Q1 2026 results showed sales of US$608.1 million and a…

Hims & Hers Health has returned to growth after a volatile period related to GLP-1 drug transitions. The company raised…

Hims & Hers Health (NYSE:HIMS) is shifting its weight loss offering from compounded GLP-1 drugs to branded medications from partners…

Hims & Hers faces profit pressure in first-quarter 2026, though subscribers increase and a Novo Nordisk GLP-1 partnership broadens weight-loss…

Hims & Hers Health, Inc.’s HIMS investors have been experiencing some short-term losses. The San Francisco, CA-based health and wellness…

Hims & Hers (HIMS) Q1-26 analysis: raised FY-26 guidance, GLP-1 margin reset, subscriber growth outlook, and a $100+ DCF value…

Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine…

NEW YORK CITY, NY / ACCESS Newswire / May 17, 2026 / Bronstein, Gewirtz & Grossman, LLC is investigating potential…

Hims & Hers continues growing rapidly, but shrinking margins and rising costs are beginning to test the companys long-term profitability…